PF-Atlas › Clinical Trials › NCT03250689
Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps in Chronic Obstructive Pulmonary Disease
Danirixin · Phase 2
Registry ID
NCT03250689
Phase
Phase 2
Status
Terminated
Drug / intervention
Danirixin
Sponsor
GlaxoSmithKline
Start
2017-11-15
About this trial
Danirixin is evaluated in NCT03250689, a Phase 2 idiopathic pulmonary fibrosis study sponsored by GlaxoSmithKline. Current status: Terminated.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT03250689 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.